Longitudinal Changes in Free-water Within the Substantia Nigra of Parkinson's Disease
Overview
Authors
Affiliations
There is a clear need to develop non-invasive markers of substantia nigra progression in Parkinson's disease. We previously found elevated free-water levels in the substantia nigra for patients with Parkinson's disease compared with controls in single-site and multi-site cohorts. Here, we test the hypotheses that free-water levels in the substantia nigra of Parkinson's disease increase following 1 year of progression, and that baseline free-water levels in the substantia nigra predict the change in bradykinesia following 1 year. We conducted a longitudinal study in controls (n = 19) and patients with Parkinson's disease (n = 25). Diffusion imaging and clinical data were collected at baseline and after 1 year. Free-water analyses were performed on diffusion imaging data using blinded, hand-drawn regions of interest in the posterior substantia nigra. A group effect indicated free-water values were increased in the posterior substantia nigra of patients with Parkinson's disease compared with controls (P = 0.003) and we observed a significant group × time interaction (P < 0.05). Free-water values increased for the Parkinson's disease group after 1 year (P = 0.006), whereas control free-water values did not change. Baseline free-water values predicted the 1 year change in bradykinesia scores (r = 0.74, P < 0.001) and 1 year change in Montreal Cognitive Assessment scores (r = -0.44, P = 0.03). Free-water in the posterior substantia nigra is elevated in Parkinson's disease, increases with progression of Parkinson's disease, and predicts subsequent changes in bradykinesia and cognitive status over 1 year. These findings demonstrate that free-water provides a potential non-invasive progression marker of the substantia nigra.
Zhou H, Wu Y, Chen S, Xing Y, Ren J, Liu W CNS Neurosci Ther. 2025; 31(2):e70277.
PMID: 39953811 PMC: 11829112. DOI: 10.1111/cns.70277.
Bower A, Chung J, Burciu R Neurosci Lett. 2025; 849:138120.
PMID: 39862921 PMC: 11851011. DOI: 10.1016/j.neulet.2025.138120.
Bergamino M, Fuentes A, Sandoval I, Marmion D, Bishop C, Manfredsson F Neuroscience. 2025; 568:2-11.
PMID: 39800048 PMC: 11871993. DOI: 10.1016/j.neuroscience.2025.01.019.
Functional and free-water imaging in rapid eye movement behaviour disorder and Parkinson's disease.
Tobin E, Arpin D, Schauder M, Higgonbottham M, Chen R, Lou X Brain Commun. 2024; 6(5):fcae344.
PMID: 39411244 PMC: 11474242. DOI: 10.1093/braincomms/fcae344.
Carpenter J, Hughes S, Filipov N Front Neurosci. 2024; 18:1465701.
PMID: 39308947 PMC: 11412963. DOI: 10.3389/fnins.2024.1465701.